Anteris Technologies Pty Ltd (ASX:AVR, NASDAQ:AVR) has appointed experienced financial executive Brent Moen as chief financial officer, effective September 12, 2026 AEST.
Moen brings more than 25 years of leadership experience across public and private companies, with expertise spanning capital markets, investor relations, mergers and acquisitions and scaling growth-focused organisations, including medical technology businesses.
Extensive medtech finance experience
Most recently, Moen served as CFO of LifeLens Technologies from September 2023 to March 2026.
Before that, he was CFO of Tactile Systems Technology between September 2018 and April 2023 and held the same role at Entellus Medical from May 2016 to March 2018.
Moen holds a Bachelor of Accountancy from the University of North Dakota.
As part of the leadership transition, current CFO Matthew McDonnell will move into the role of head of Australia from September 12, 2026 AEST and will cease serving as chief financial officer.
About Anteris
Anteris is developing medical devices aimed at restoring healthy heart function in patients with structural heart disease.
Its lead product is the DurAVR® Transcatheter Heart Valve, designed to treat aortic stenosis and shaped to mimic the performance and blood-flow characteristics of a healthy human aortic valve.
The balloon-expandable valve uses Anteris’ patented ADAPT® anti-calcification tissue technology, which has been used clinically for more than 10 years and distributed for use in more than 55,000 patients worldwide.
The DurAVR® system combines the valve and ADAPT® tissue with the company’s balloon-expandable ComASUR® Delivery System.
